2019 IPO

Adaptive Biotechnologies Stock

DNA sequencing for cancer therapy & research

Sign up today and learn more about Adaptive Biotechnologies Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Tiger Management Corporation


Seattle WA, US

Total Funding


About Adaptive Biotechnologies Stock

Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune system cells rearrange their DNA constantly in response to shifting threats in the environment. Sometimes the immune system malfunctions and begins attacking healthy tissues (i.e., autoimmune diseases) or certain immune system cells start proliferating out of control (i.e., cancer). 

By digging into the immune cell sequences, Adaptive is aiming to create a map of human immune system responses to threats.  Armed with this information, Adaptive seeks to develop blood tests that alert doctors when people are fighting specific diseases.  Eventually, Adaptive wants to create a universal blood test that detects any disease a body might be fighting.  Although such an all-encompassing test may be 10 years away, intermediate tests will come much sooner, according to CEO Chad Robins.

Adaptive was founded in 2009 by Chad RobinsChristopher Carlson, and Harlan Robins and is based in Seattle, Washington.  The company has raised capital from investors such as Microsoft, Matrix Capital Management, Tiger Management and Viking Global Investors.

Source: Seattle Times; Crunchbase; Forbes

Overview of Adaptive Biotechnologies:

Source: WBBA TV


Funding History

September 2009$4.5M
May 2011$9.7M
June 2013$12.7M
April 2014$107M
January 2015$93.7M
January 2015$105M
May 2015$195M
December 2017$51.2M


Co-Founder and CEO

Chad Robins

Co-Founder and Head of Innovation

Harlan Robins


Chad Cohen


Sean Nolan


Julie Rubinstein


Business Wire (press release) - Apr, 2 2018

FDA Approves First Therapy for Patients with MRD-Positive ALL

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: